Pharmaceutical

AAIC 2024: Eisai presents positive long-term data with Leqembi

Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.

Aug 3, 2024 - 04:00
AAIC 2024: Eisai presents positive long-term data with Leqembi
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
Read the original article

Tags:

Previous Article

AbbVie acquires Cerevel Therapeutics for $8.7bn

Next Article

Agios Fails to Reach Primary Objective in Pediatric Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca

STAT+: In lung cancer, J&J data amount to latest salvo ...

Oct 24, 2023

STAT+: As demand for Covid shots wanes, Moderna seeks its next success

STAT+: As demand for Covid shots wanes, Moderna seeks i...

Jun 26, 2023

STAT+: Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

STAT+: Eli Lilly to acquire DICE Therapeutics in $2.4 b...

Jun 20, 2023